WO2021150713A2 - Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e - Google Patents

Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e Download PDF

Info

Publication number
WO2021150713A2
WO2021150713A2 PCT/US2021/014360 US2021014360W WO2021150713A2 WO 2021150713 A2 WO2021150713 A2 WO 2021150713A2 US 2021014360 W US2021014360 W US 2021014360W WO 2021150713 A2 WO2021150713 A2 WO 2021150713A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
subject
composition
cell
vector
Prior art date
Application number
PCT/US2021/014360
Other languages
English (en)
Other versions
WO2021150713A3 (fr
Inventor
Jeffrey Schlom
Claudia M. Palena
Renee N. DONAHUE
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2021150713A2 publication Critical patent/WO2021150713A2/fr
Publication of WO2021150713A3 publication Critical patent/WO2021150713A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Definitions

  • HERVs Human Endogenous Retroviruses
  • HERVs are remnant of retrovirus germ line infections early in primate evolution and are not viruses.
  • HERVs represent approximately 8% of the human genome. They are an extremely diverse group constituted by at least 3 major classes: Class I consisting of HERV-H, HHLA2 and HERV-E, among others; Class II consisting of HERV-K, among others; and a very diverse Class III.
  • HERV-HEMO has not yet been classified.
  • HERVs encode env and gag sequences with a similar organization to Retroviridae, and they can be epigenetically regulated.
  • the invention provides a peptide comprising, consisting essentially of, or consisting of the amino acid sequence of any one of SEQ ID NOs: 1-41.
  • the invention provides a polypeptide (protein) comprising the peptide; a nucleic acid encoding the peptide; a vector comprising the nucleic acid; a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector; and compositions thereof.
  • the invention provides a method of inhibiting cancer in a subject comprising administering a therapeutically effective amount of a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to the subject to the subject, wherein cancer in the subject is inhibited.
  • the invention also provides a method of enhancing an immune response against cancer in a subject comprising administering a therapeutically effective amount of a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to the subject, wherein the immune response in the subject is enhanced.
  • the invention also provides a method of treating cancer in a subject comprising administering a therapeutically effective amount of a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to the subject.
  • the invention also provides a method of reducing, arresting, reversing or preventing the metastatic progression of cancer in a subject comprising administering a therapeutically effective amount of a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to the subject.
  • the invention also provides a method of preventing or delaying the onset of cancer in a subject comprising administering a therapeutically effective amount of a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to the subject.
  • the invention further provides a method of inhibiting cancer in a subject comprising (a) obtaining (isolating) lymphocytes from the subject, (b) stimulating the lymphocytes with a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to the subject to generate cytotoxic T lymphocytes ex vivo, and (c) administering the cytotoxic T lymphocytes to the subject, wherein cancer in the subject is inhibited.
  • the invention provides a method of inhibiting cancer in a subject comprising (a) obtaining (isolating) dendritic cells from the subject, (b) treating the dendritic cells with a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell ex vivo, and (c) administering the treated dendritic cells to the subject, wherein cancer in the subject is inhibited.
  • the invention provides inhibiting cancer in a subject comprising (a) obtaining peripheral blood mononuclear cells (PBMCs) from a subject suffering from cancer, (b) isolating dendritic cells from the PBMCs, (c) treating the dendritic cells with a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell ex vivo, (d) activating the PBMCs with the treated dendritic cells ex vivo, and (e) administering the activated PBMCs to the subject, wherein cancer in the subject is inhibited.
  • PBMCs peripheral blood mononuclear cells
  • the invention further provides inhibiting cancer in a subject comprising (a) obtaining peripheral blood mononuclear cells (PBMCs) from a subject suffering from cancer, (b) isolating dendritic cells from the PBMCs, (c) treating the dendritic cells with a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell ex vivo, (d) activating the PBMCs with the treated dendritic cells ex vivo, (e) isolating T lymphocytes from the activated PBMCs ex vivo, and (f) administering the isolated T lymphocytes to the subject, wherein cancer in the subject is inhibited.
  • PBMCs peripheral blood mononuclear cells
  • the invention provides the use of adoptively transferred T cells stimulated in vitro with a composition comprising the peptide, polypeptide (protein), nucleic acid, vector, or cell to treat cancer, to inhibit cancer, to reduce, arrest, reverse, or prevent the metastatic progression of cancer in a subject, or to prevent or delay the onset of cancer.
  • the invention provides a method of inducing an immune response against cancer in a subject comprising (a) administering to the subject a first vector (e.g., viral vector, such as poxviral vector) comprising a nucleic acid encoding the amino acid sequence of any one of SEQ ID NOs: 1-41 and (b) administering to the subject a second vector (e.g., viral vector, such as poxviral vector) comprising a nucleic acid encoding the amino acid sequence of any one of SEQ ID NOs: 1-41.
  • a first vector e.g., viral vector, such as poxviral vector
  • a second vector e.g., viral vector, such as poxviral vector
  • the invention also provides a method for inhibiting cancer in a subject comprising administering T cell receptor (TCR) engineered T cells or TCR engineered NK cells to the subject, wherein the TCR recognizes one or more epitopes of H, K, and E human endogenous retroviruses (HERVs).
  • TCR T cell receptor
  • HERVs E human endogenous retroviruses
  • Figure 1 depicts the expression of HERV-H1, HERV-H3, and HERV-K env in normal tissues. Expression of indicated transcripts was performed in pooled human normal tissues by RT-PCR. Expression of each transcript is relative to control b-actin. In the graph on the right, expression is depicted for each tissue type in the following order: HERV-H1 env, HERV-H3 env, and HERV-K env.
  • Figure 2 depicts the expression of HERV-H1, HERV-H3, and HERV-K env in cancer tissues. Expression of indicated transcripts was performed in human cancer tissues by RT-PCR. Each sample corresponds to a single tumor tissue b-actin was used as internal control.
  • Figure 3 depicts the expression of HERV-H1, HERV-H3, and HERV-K env in cancer versus normal tissues. The comparative expression of indicated transcripts in tumor (left) versus normal tissues (right), normalized to b-actin, is shown. Expression is depicted for each tissue type in the following order: HERV-H1 env, HERV-H3 env, and HERV-K env.
  • FIG 4 depicts cell-based peptide binding and stability assay of HERV-H env peptides.
  • T2A2 cells were incubated overnight with indicated concentrations of peptides and binding was evaluated by FACS analysis.
  • Right panel stability of MHC/peptide complexes was evaluated by FACS analysis over time following treatment with brefeldin A (BFA).
  • Figure 5 depicts cell-based peptide binding and stability assay of HERV-K env peptides. Evaluations were performed as in Figure 4. Best binder: HERV-K env 450 native: ILTEVLKGV (SEQ ID NO: 17).
  • the invention provides human immunogenic epitopes of H, K, and E human endogenous retroviruses (HERVs), which can be used in vaccines and other compositions for the prevention or therapeutic treatment of cancer.
  • HERVs human endogenous retroviruses
  • the invention provides peptides, polypeptides, and proteins comprising, consisting essentially of, or consisting of the amino acid sequence of any one of SEQ ID NOs: 1-41.
  • the invention provides a polypeptide that comprises the HERV H envelope or fragment thereof (e.g., HERV HI or HERV H3), wherein one or more of the corresponding amino acid residues have been replaced with one or more of the enhancer agonist epitopes of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 15, 16, and 38.
  • the invention provides a polypeptide that comprises the HERV H envelope or fragment thereof (e.g., HERV HI or HERV H3), wherein one or more of the corresponding amino acid residues have been replaced with one or more of the enhancer agonist epitopes of SEQ ID NOs: 4, 8, 10, 12, 15, 16, and 38.
  • the invention provides a polypeptide that comprises the HERV K envelope or fragment thereof, wherein the corresponding amino acid residues have been replaced with one or more of the enhancer agonist epitopes of SEQ ID NOs: 20, 21, 23, 25, 26, and 28.
  • the invention provides a polypeptide that comprises the HERV K envelope or fragment thereof, wherein the corresponding amino acid residues have been replaced with one or more of the enhancer agonist epitopes of SEQ ID NOs: 20, 21, 25, 26, and 28.
  • a “polypeptide” is generally understood to be a linear organic polymer consisting of a large number of amino acid residues bonded together in a continuous, unbranched chain, forming part of, or the whole of, a protein molecule.
  • a “peptide” is generally considered to be distinguished from a full-length protein or polypeptide on the basis of size, and, in one embodiment, as an arbitrary benchmark can be understood to contain approximately 50 or fewer amino acids, while polypeptides or full-length proteins are generally longer.
  • the terms “peptide” and “polypeptide” can be used interchangeably in some embodiments to describe a protein useful in the present invention, or the term “protein” can be used generally.
  • the inventive peptide or polypeptide can be any suitable length.
  • a peptide of the invention has no more than 25 (e.g., no more than 24, no more than 23, no more than 22, no more than 21, no more than 20, no more than 19, no more than 18, no more than 17, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, or no more than 10) amino acid residues.
  • the additional amino acid residues, if present, preferably are from the corresponding HERVs proteins (e.g., HERV-H env, HERV-K env, HERV-K gag, or HERV-E env).
  • a polypeptide for expression in a host cell such as a yeast, is of a minimum size capable of being expressed recombinantly in the host cell.
  • the polypeptide that is expressed by the host cell is preferably at least 25 amino acids in length, and is typically at least or greater than 25 amino acids in length, or at least or greater than 26 amino acids, at least or greater than 27 amino acids, at least or greater than 28 amino acids, at least or greater than 29 amino acids, at least or greater than 30 amino acids, at least or greater than 31 amino acids, at least or greater than 32 amino acids, at least or greater than 33 amino acids, at least or greater than 34 amino acids, at least or greater than 35 amino acids, at least or greater than 36 amino acids, at least or greater than 37 amino acids, at least or greater than 38 amino acids, at least or greater than 39 amino acids, at least or greater than 40 amino acids, at least or greater than 41 amino acids, at least or greater than 42 amino acids, at least or greater than 43 amino acids, at least or greater than 44 amino acids, at least or greater than 45 amino acids, at least or greater than 46 amino acids, at least or greater than 47 amino acids, at least or greater than 48 amino acids, at least or greater than 49 amino acids, at
  • Peptides and polypeptides (proteins) of the invention are, in some embodiments of the invention, used as antigens.
  • the general use herein of the term “antigen” refers to any portion of a protein (e.g., peptide, partial protein, full-length protein), wherein the protein is naturally occurring or synthetically derived or designed, to a cellular composition (whole cell, cell lysate or disrupted cells), to an organism (whole organism, lysate or disrupted cells), or to a carbohydrate, or other molecule, or a portion thereof.
  • An antigen may elicit an antigen-specific immune response (e.g., a humoral and/or a cell-mediated immune response) against the same or similar antigens that are encountered in vitro, in vivo, or ex vivo by an element of the immune system (e.g., T cells, antibodies).
  • an antigen-specific immune response e.g., a humoral and/or a cell-mediated immune response
  • an element of the immune system e.g., T cells, antibodies
  • An antigen can be as small as a single epitope (e.g., SEQ ID NOs: 1-41 described herein), a single immunogenic domain or larger, and can include multiple epitopes or immunogenic domains.
  • the size of a protein antigen can be as small as about 8-11 amino acids (e.g., a peptide) and as large as a domain of a protein, a full-length protein, a multimer, a fusion protein, or a chimeric protein.
  • Antigens useful in various immunotherapeutic compositions described herein include peptides, polypeptides, protein domain(s) (e.g., immunogenic domains), protein subunits, full-length proteins, multimers, fusion proteins, and chimeric proteins.
  • immunogen When referring to stimulation of an immune response, the term “immunogen” is a subset of the term “antigen” and, therefore, in some instances, can be used interchangeably with the term “antigen.”
  • An immunogen describes an antigen which elicits a humoral and/or cell-mediated immune response (i.e., is immunogenic), such that administration of the immunogen to an individual mounts an antigen-specific immune response against the same or similar antigens that are encountered by the immune system of the individual.
  • the immunogen elicits a cell- mediated immune response, including a CD4 + T cell response (e.g., TH1, TH2, and/or TH17) and/or a CD8 + T cell response (e.g., a CTL response).
  • a CD4 + T cell response e.g., TH1, TH2, and/or TH17
  • a CD8 + T cell response e.g., a CTL response
  • an “immunogenic domain” or “immunological domain” of a given protein can be any portion, fragment or epitope of an antigen (e.g., a peptide fragment or subunit or an antibody epitope or other conformational epitope) that contains at least one epitope that can act as an immunogen when administered to an animal. Therefore, an immunogenic domain is larger than a single amino acid and is at least of a size sufficient to contain at least one epitope that can act as an immunogen. For example, a single protein can contain multiple different immunogenic domains. Immunogenic domains need not be linear sequences within a protein, such as in the case of a humoral immune response, where conformational domains are contemplated.
  • An epitope is defined herein as a single immunogenic site within a given antigen that is sufficient to elicit an immune response when provided to the immune system in the context of appropriate costimulatory signals and/or activated cells of the immune system.
  • an epitope is the part of an antigen that is recognized by components of the immune system, and may also be referred to as an antigenic determinant.
  • T cell epitopes are different in size and composition from B cell or antibody epitopes, and that epitopes presented through the Class I MHC pathway differ in size and structural attributes from epitopes presented through the Class II MHC pathway.
  • T cell epitopes presented by Class I MHC molecules are typically between 8 and 11 amino acids in length, whereas epitopes presented by Class II MHC molecules are less restricted in length and may be up to 25 amino acids or longer.
  • T cell epitopes have predicted structural characteristics depending on the specific MHC molecules bound by the epitope. Epitopes can be linear sequence epitopes or conformational epitopes (conserved binding regions). Most antibodies recognize conformational epitopes.
  • a “target antigen” is an antigen that is specifically targeted by an immunotherapeutic composition of the invention (i.e., an antigen, usually the native antigen, against which elicitation of an immune response is desired, even if the antigen used in the immunotherapeutic is an agonist of the native antigen).
  • a “cancer antigen,” which also is referred to as a tumor-associated antigen (TAA), is an antigen that comprises at least one antigen that is associated with a cancer, such as an antigen expressed by a tumor cell, so that targeting the antigen also targets the tumor cell and/or cancer.
  • a cancer antigen can include one or more antigens from one or more proteins, including one or more tumor- associated proteins.
  • a peptide, protein, or polypeptide useful in the present invention comprises, consists essentially of, or consists of at least one of peptides represented by SEQ ID NOs: 1-41.
  • other epitopes can be additionally included in an antigen for use in the present invention.
  • a HERVs antigen useful in the present invention may include one or more additional amino acid mutations (substitutions, insertions or deletions), for example, to inactivate or delete a natural biological function of the native protein (e.g., to improve expression or enhance safety of the antigen).
  • the peptide or polypeptide (protein) of the invention can be prepared by any method, such as by synthesizing the peptide or by expressing a nucleic acid encoding an appropriate amino acid sequence for the peptide or polypeptide in a cell and, in some embodiments, harvesting the peptide or polypeptide from the cell. In some embodiments, the peptide or polypeptide is not harvested from the cell, such as in embodiments of the invention directed to a yeast-based immunotherapy composition, which is described in detail below. A combination of such methods of production of peptides and polypeptides also can be used. Methods of de novo synthesizing peptides and methods of recombinantly producing peptides or polypeptides are known in the art
  • the invention also provides a nucleic acid molecule comprising a nucleic acid sequence encoding the peptide or the polypeptide.
  • the nucleic acid molecule can comprise DNA (genomic or cDNA) or RNA, and can be single or double stranded.
  • the nucleic acid molecule can comprise nucleotide analogues or derivatives (e.g., inosine or phophorothioate nucleotides and the like).
  • the nucleic acid sequence can encode the peptide or polypeptide alone or as part of a fusion protein.
  • the nucleic acid sequence encoding the peptide or polypeptide can be provided as part of a construct comprising the nucleic acid molecule and elements that enable delivery of the nucleic acid molecule to a cell, and/or expression of the nucleic acid molecule in a cell.
  • elements include, for example, expression vectors, promoters, and transcription and/or translation control sequences.
  • constructs can also be referred to as “recombinant nucleic acid molecules.” Suitable vectors, promoters, transcription/translation sequences, and other elements, as well as methods of preparing such nucleic acid molecules and constructs, are known in the art.
  • nucleic acid molecule primarily refers to the physical nucleic acid molecule and the phrase “nucleic acid sequence” primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a peptide or polypeptide.
  • recombinant nucleic acid molecule primarily refers to a nucleic acid molecule operatively linked to an element such as a transcription control sequence, but can be used interchangeably with the phrase “nucleic acid molecule.”
  • the invention further provides a vector comprising the nucleic acid molecule.
  • suitable vectors include plasmids (e.g., DNA plasmids), yeast, listeria, and viral vectors, such as poxvirus, retrovirus, adenovirus, adeno-associated virus, herpes virus, polio virus, alphavirus, baculorvirus, and Sindbis virus.
  • the vector is a plasmid (e.g., DNA plasmid).
  • the plasmid can be complexed with chitosan.
  • the vector is a poxvirus (e.g., chordopox virus vectors and entomopox virus vectors).
  • poxviruses include orthopox, avipox, parapox, yatapox, and molluscipox, raccoon pox, rabbit pox, capripox (e.g., sheep pox), leporipox, and suipox (e.g., swinepox).
  • avipox viruses include fowlpox, pigeonpox, canarypox, such as ALVAC, mynahpox, uncopox, quailpox, peacockpox, penguinpox, sparrowpox, starlingpox, and turkeypox.
  • orthopox viruses include smallpox (also known as variola), cowpox, monkeypox, vaccinia, ectromelia, camelpox, raccoonpox, and derivatives thereof.
  • vaccinia virus refers to both the wild-type vaccinia virus and any of the various attenuated strains or isolates subsequently isolated including, for example, modified vaccinia Ankara (MV A), NYVAC, TROYVAC, Dry-Vax (also known as vaccinia virus-Wyeth), POXVAC-TC (Schering-Plough Corporation), vaccinia virus- Westem Reserve, vaccinia virus-EM63, vaccinia virus-Lister, vaccinia virus-New York City Board of Health, vaccinia virus-Temple of Heaven, vaccinia virus-Copenhagen, ACAM1000, ACAM2000, and modified vaccinia virus Ankara-Bavarian Nordic (“MVA- BN”).
  • MV A modified vaccinia Ankara
  • NYVAC NYVAC
  • TROYVAC Dry-Vax
  • Dry-Vax also known as vaccinia virus-Wyeth
  • POXVAC-TC St
  • the MV A is selected from the group consisting of MVA-572, deposited at the European Collection of Animal Cell Cultures (“ECACC”), Health Protection Agency, Microbiology Services, Porton Down, Salisbury SP4 0JG, United Kingdom (“UK”), under the deposit number ECACC 94012707 on January 27,
  • MVA-575 deposited at the ECACC under deposit number ECACC 00120707 on December 7, 2000
  • MVA-Bavarian Nordic (“MVA-BN”) deposited at the ECACC under deposit number V00080038 on August 30, 2000
  • derivatives of MVA-BN Additional exemplary poxvirus vectors are described in U.S. Patent No. 7,211,432.
  • the vaccinia virus MVA was generated by 516 serial passages on chicken embryo fibroblasts of the Ankara strain of Vaccinia virus, referred to as chorioallantois virus Ankara (CVA) (see Mayr et al., Infection, 3: 6-14 (1975)).
  • CVA chorioallantois virus Ankara
  • the genome of the resulting attenuated MVA lacks approximately 31 kilobase pairs of genomic DNA compared to the parental CVA strain and is highly host-cell restricted to avian cells (see Meyer et al., J. Gen. Virol., 72. 1031-1038 (1991)). It was shown in a variety of animal models that the resulting MVA was significantly avirulent (Mayr et al., Dev. Biol.
  • MVA- BN is preferred for its better safety profile because it is less replication competent than other MVA strains
  • all MV As are suitable for this invention, including MVA-BN and its derivatives.
  • Both MVA and MVA-BN are able to efficiently replicate their DNA in mammalian cells even though they are avirulent. This trait is the result of losing two important host range genes among at least 25 additional mutations and deletions that occurred during its passages through chicken embryo fibroblasts (see Meyer et al., Gen. Virol., 72: 1031-1038 (1991); and Antoine et al., Virol., 244: 365-396 (1998)).
  • MVA can be used in conditions of pre-existing poxvirus immunity (Ramirez et al., J. Virol., 74: 7651-7655 (2000)).
  • MVA and MVA-BN lack approximately 15% (31 kb from six regions) of the genome compared with the ancestral chorioallantois vaccinia virus Ankara (“CVA”). The deletions affect a number of virulence and host range genes, as well as the gene for Type A inclusion bodies. MVA-BN can attach to and enter human cells where virally- encoded genes are expressed very efficiently. However, assembly and release of progeny virus does not occur. MVA-BN is strongly adapted to primary chicken embryo fibroblast (CEF) cells and does not replicate in human cells. In human cells, viral genes are expressed, and no infectious virus is produced.
  • CAF primary chicken embryo fibroblast
  • MVA-BN has been shown to elicit both humoral and cellular immune responses to vaccinia and to heterologous gene products encoded by genes cloned into the MVA genome (see Harrer et al., Antivir. Ther., 40(2): 285-300 (2005); Cosma et al., Vaccine, 22(1): 21-29 (2003); Di Nicola et al., Hum. Gene Ther., 14(14): 1347-1360 (2003); and Di Nicola et al., Clin. Cancer Res., 10(16): 5381-5390 (2004)).
  • the reproductive replication of a virus is typically expressed by the amplification ratio.
  • the term “amplification ratio” refers to the ratio of virus produced from an infected cell (“output”) to the amount originally used to infect the cells in the first place (“input”).
  • An amplification ratio of “1” defines an amplification status in which the amount of virus produced from infected cells is the same as the amount initially used to infect the cells, which means that the infected cells are permissive for virus infection and reproduction.
  • An amplification ratio of less than 1 means that infected cells produce less virus than the amount used to infect the cells in the first place, and indicates that the virus lacks the capability of reproductive replication, which is a measure of virus attenuation.
  • the term “not capable of reproductive replication” means that an MVA or MVA derivative has an amplification ratio of less than 1 in one or more human cell lines, such as, for example, the human embryonic kidney 293 cell line (HEK293, which is deposited under deposit number ECACC No. 85120602), the human bone osteosarcoma cell line 143B (deposited under deposit number ECACC No. 91112502), the human cervix adenocarcinoma cell line HeLa (deposited at the American Type Culture Collection (ATTC) under deposit number ATCC No. CCL-2), and the human keratinocyte cell line HaCat (see Boukamp et al, J. Cell Biol., 106(3): 761-71 (1988)).
  • human embryonic kidney 293 cell line HEK293, which is deposited under deposit number ECACC No. 85120602
  • the human bone osteosarcoma cell line 143B deposited under deposit number ECACC No. 91112502
  • MVA-BN does not reproductively replicate in the human cell lines HEK293, 143B, HeLa, and HaCat (see U.S. Patent Nos. 6,761,893 and 6,193,752, and International Patent Application Publication No. WO 2002/042480).
  • MVA-BN exhibited an amplification ratio of 0.05 to 0.2 in HEK293 cells, an amplification ratio of 0.0 to 0.6 in 143B cells, an amplification ratio of 0.04 to 0.8 in HeLa cells, and an amplification ratio of 0.02 to 0.8 in HaCat cells.
  • MVA-BN does not reproductively replicate in any of the human cell lines HEK293, 143B, HeLa, and HaCat.
  • MVA-BN the amplification ratio of MVA-BN is greater than 1 in primary cultures of chicken embryo fibroblast cells (CEF) and in baby hamster kidney cells (BHK, which is deposited under deposit number ATCC No. CRL-1632). Therefore MVA-BN can easily be propagated and amplified in CEF primary cultures with an amplification ratio above 500, and in BHK cells with an amplification ratio above 50.
  • CEF chicken embryo fibroblast cells
  • BHK baby hamster kidney cells
  • MV As are suitable for this invention, including MVA-BN and its derivatives.
  • derivatives refers to viruses showing essentially the same replication characteristics as the strain deposited with ECACC on August 30, 2000, under deposit number ECACC No. V00080038 but showing differences in one or more parts of its genome.
  • Viruses having the same “replication characteristics” as the deposited virus are viruses that replicate with similar amplification ratios as the deposited strain in CEF cells, in BHK cells, and in the human cell lines HEK293, 143B, HeLa, and HaCat.
  • the vector When the vector is for administration to a subject (e.g., human), the vector (e.g., poxvirus) preferably has a low replicative efficiency in a target cell (e.g., no more than about 1 progeny per cell or, more preferably, no more than 0.1 progeny per cell are produced). Replication efficiency can readily be determined empirically by determining the virus titer after infection of the target cell.
  • a target cell e.g., no more than about 1 progeny per cell or, more preferably, no more than 0.1 progeny per cell are produced.
  • Replication efficiency can readily be determined empirically by determining the virus titer after infection of the target cell.
  • a vector useful in the invention e.g., a plasmid or a viral vector
  • a vector useful in the invention also can comprise a nucleic acid sequence encoding one or more immunostimulatory/regulatory molecules, granulocyte macrophage colony stimulating factor (GM-CSF), cytokines, and/or molecules that can enhance an immune response (e.g., additional tumor-associated antigens).
  • GM-CSF granulocyte macrophage colony stimulating factor
  • cytokines e.g., additional tumor-associated antigens
  • TAAs tumor-associated antigens
  • AFP 5-a-reductase
  • AM-1 a-fetoprotein
  • APC April
  • BAGE B melanoma antigen gene
  • BAGE B melanoma antigen gene
  • CA-125 CA-125
  • caspase-8 also known as FLICE
  • Cathepsins CD 19, CD20, CD21/complement receptor 2 (CR2), CD22/BL-CAM, CD23/Fc ⁇ RII, CD33, CD35/complement receptor 1 (CR1), CD44/PGP-1, CD45/leucocyte common antigen (LCA), CD46/membrane cofactor protein (MCP), CD52/CAMPATH-1, CD55/decay accelerating factor (DAF), CD59/protectin, CDC27, CDK4, carcinoembryonic antigen (CEA), c-myc, cycl
  • Rb RCAS1, mutated Ras, SART-1, SSX-family, STAT3, STn, TAG-72, transforming growth factor-alpha (TGF-a), transforming growth factor-beta (TGF-b), Thymosin-beta- 15, tumor necrosis factor-alpha (TNF-a), TP1, TRP-2, tyrosinase, vascular endothelial growth factor (VEGF), ZAG, pl6INK4, and glutathione-S-transferase (GST), as well as modified versions thereof (e.g., CEA-6D).
  • the nucleic acid encoding the peptide, as well as any other exogenous gene(s), preferably are inserted into a site or region (insertion region) in the vector (e.g., poxvirus) that does not affect virus viability of the resultant recombinant virus.
  • a site or region insertion region
  • regions can be readily identified by testing segments of virus DNA for regions that allow recombinant formation without seriously affecting virus viability of the recombinant virus.
  • TK thymidine kinase
  • insertion regions include, but are not limited to, the BamHI J fragment, EcoRI-Hindlll fragment, BamHI fragment, EcoRV-Hindlll fragment, long unique sequence (LUS) insertion sites (e.g.,
  • insertion sites include, but are not limited to, 44/45, 49/50, and 124/125.
  • the vector is a recombinant fowlpox virus comprising a nucleic acid encoding the peptide and/or other exogenous gene(s) (e.g., encoding one or more immunostimulatory/regulatory molecules)
  • the nucleic acid encoding the peptide can be inserted in one region (e.g., the FP14 region), and the exogenous gene(s) can be inserted in another region (e.g., the BamHI J region).
  • the inventive vector can include suitable promoters and regulatory elements, such as a transcriptional regulatory element or an enhancer.
  • suitable promoters include the SV40 early promoter, an RSV promoter, the retrovirus LTR, the adenovirus major late promoter, the human CMV immediate early I promoter, and various poxvirus promoters, such as the Pr7.5K promoter, 30K promoter, 40K promoter, 13 promoter, Prs promoter, PrsSynllm promoter, PrLEl promoter, synthetic early /late (sE/L) promoter, HH promoter,
  • a cell comprising (1) the peptide or polypeptide, (2) a nucleic acid molecule encoding the peptide or polypeptide, and/or (3) a vector comprising the nucleic acid molecule also is provided herein.
  • Suitable cells include prokaryotic and eukaryotic cells, e.g., mammalian cells, yeast, fungi other than yeast, and bacteria (such as E. coli).
  • the cell can be used in vitro, such as for research or for production of the peptide or polypeptide, or the cell can be used in vivo.
  • the cell is a yeast cell, which may be used to provide a yeast vehicle component of the yeast-based immunotherapy composition as described herein.
  • the cell can be a peptide-pulsed antigen presenting cell. Suitable antigen presenting cells include, but are not limited to, dendritic cells, B lymphocytes, monocytes, macrophages, and the like.
  • the cell is dendritic cell.
  • Dendritic cells of different maturation stages can be isolated based on the cell surface expression markers. For example, mature dendritic cells are less able to capture new proteins for presentation but are much better at stimulating resting T cells to grow and differentiate. Thus, mature dendritic cells can be of importance. Mature dendritic cells can be identified by their change in morphology and by the presence of various markers. Such markers include, but are not limited to, cell surface markers such as B7.1, B7.2, CD40, CD11, CD83, and MHC class II. Alternatively, maturation can be identified by observing or measuring the production of pro-inflammatory cytokines.
  • Dendritic cells can be collected and analyzed using typical cytofluorography and cell sorting techniques and devices, such as a fluorescence-activated cell sorter (FACS).
  • FACS fluorescence-activated cell sorter
  • Antibodies specific to cell surface antigens of different stages of dendritic cell maturation are commercially available.
  • the peptide, polypeptide, nucleic acid, vector, or cell can be isolated.
  • isolated encompasses compounds or compositions that have been removed from a biological environment (e.g., a cell, tissue, culture medium, body fluid, etc.) or otherwise increased in purity to any degree (e.g., isolated from a synthesis medium).
  • Isolated compounds and compositions thus, can be synthetic or naturally produced.
  • the peptide, polypeptide, nucleic acid, vector, or cell can be formulated as a composition (e.g., pharmaceutical composition) comprising the peptide, polypeptide, nucleic acid, vector, or cell and a carrier (e.g., a pharmaceutically or physiologically acceptable carrier).
  • a carrier e.g., a pharmaceutically or physiologically acceptable carrier.
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition of the invention can be used in the methods described herein alone or as part of a pharmaceutical formulation.
  • composition e.g., pharmaceutical composition
  • compositions can comprise more than one peptide, polypeptide, nucleic acid, vector, or cell of the invention.
  • Vectors and compositions of the invention can further include or can be administered with (concurrently, sequentially, or intermittently with) any other agents or compositions or protocols that are useful for inhibiting, preventing, or treating cancer or any compounds that treat or ameliorate any symptom of cancer.
  • the composition can comprise one or more other pharmaceutically active agents or drugs.
  • anticancer agents e.g., chemotherapeutic or radiotherapeutic agents
  • antimetabolites hormones, hormone antagonists, antibiotics, antiviral drugs, antifungal drugs, cyclophosphamide, and combinations thereof.
  • Suitable anticancer agents include, without limitation, alkylating agents, folate antagonists, purine antagonists, pyrimidine antagonists, spindle poisons, topoisomerase inhibitors, apoptosis inducing agents, angiogenesis inhibitors, podophyllotoxins, nitrosoureas, cisplatin, carboplatin, interferon, asparginase, tamoxifen, leuprolide, flutamide, megestrol, mitomycin, bleomycin, doxorubicin, irinotecan, taxol, geldanamycin (e.g., 17-AAG), and various anti-cancer peptides and antibodies known in the art.
  • alkylating agents include, without limitation, alkylating agents, folate antagonists, purine antagonists, pyrimidine antagonists, spindle poisons, topoisomerase inhibitors, apoptosis inducing agents, angiogenesis inhibitors, podophyllotoxins
  • alkylating agents include, but are not limited to, nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, melphalan, uracil mustard, or chlorambucil), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozocin, or dacarbazine).
  • nitrogen mustards e.g., mechlorethamine, cyclophosphamide, melphalan, uracil mustard, or chlorambucil
  • alkyl sulfonates e.g., busulfan
  • nitrosoureas e.g., carmustine, lomustine, semustine, streptozocin, or dacarbazine.
  • Exemplary antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., 5-fluorouracil (5-FU) or cytarabine), and purine analogs (e.g., mercaptopurine or thioguanine).
  • folic acid analogs e.g., methotrexate
  • pyrimidine analogs e.g., 5-fluorouracil (5-FU) or cytarabine
  • purine analogs e.g., mercaptopurine or thioguanine
  • hormones and hormone antagonists include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxy progesterone caproate, medroxyprogesterone acetate, and magestrol acetate), estrogens (e.g., diethylstilbestrol and ethinyl estradiol), antiestrogens (e.g., tamoxifen), and androgens (e.g., testosterone proprionate and fluoxymesterone).
  • adrenocorticosteroids e.g., prednisone
  • progestins e.g., hydroxy progesterone caproate, medroxyprogesterone acetate, and magestrol acetate
  • estrogens e.g., diethylstilbestrol and ethinyl estradiol
  • antiestrogens e.g., tamoxi
  • exemplary agents include, but are not limited to, vinca alkaloids (e.g., vinblastine, vincristine, or vindesine), epipodophyllotoxins (e.g., etoposide or teniposide), antibiotics (e.g., dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or mitocycin C), enzymes (e.g., L-asparaginase), platinum coordination complexes (e.g., cis-diamine-dichloroplatinum II also known as cisplatin), substituted ureas (e.g., hydroxyurea), methyl hydrazine derivatives (e.g., procarbazine), and adrenocortical suppressants (e.g., mitotane and aminoglutethimide).
  • vinca alkaloids e.g., vinblastine, vincristine, or vinde
  • Chemotherapeutics that can be concurrently, sequentially or intermittently administered with the vectors and compositions disclosed herein include Adriamycin, Alkeran, Ara-C, Busulfan, CCNU, Carboplatinum, Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU, Fludarabine, Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin, Mitoxantrone, Nitrogen Mustard, Taxol (or other taxanes, such as docetaxel), Velban, Vincristine, VP- 16, Gemcitabine (Gemzar), Herceptin, Irinotecan (Camptosar, CPT-11), Leustatin, Navelbine, Rituxan STI-571, Taxotere, Topotecan (Hycamtin), Xeloda (Capecitabine), Zevelin, Enzalutamide (MDV-3100 or XT
  • immunomodulators and/or cytokines include, but are not limited to, AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (granulocyte macrophage colony stimulating factor; Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immune globulin (Cutter Biological), IMREG (from Imreg of New La, La.), SK&F 106528, tumor necrosis factor (TNF)-a, and TNF-b.
  • compositions or protocols that are useful for the treatment of cancer in conjunction with the peptides, polypeptides (proteins), nucleic acids, vectors, cells, and compositions of the invention include, but are not limited to, surgical resection of a tumor, radiation therapy, allogeneic or autologous stem cell transplantation, T cell adoptive transfer, and/or targeted cancer therapies (e.g., small molecule drugs, biologies, or monoclonal antibody therapies that specifically target molecules involved in tumor growth and progression, including, but not limited to, selective estrogen receptor modulators (SERMs), aromatase inhibitors, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, histone deacetylase (HD AC) inhibitors, retinoid receptor activators, apoptosis stimulators, angiogenesis inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, or immunostimulators
  • SERMs selective estrogen receptor modulators
  • the agent can be a cancer vaccine, such as PANVAC, PROSTVAC, MVA-Brachyury TRICOM, yeast- Brachyury, AdCEA Avelumab (Avel) Folfox, CEA-MUC-TRICOM CV301, or Bacillus Calmette-Guerin (BCG) alone or combined with PANVAC.
  • a cancer vaccine such as PANVAC, PROSTVAC, MVA-Brachyury TRICOM, yeast- Brachyury, AdCEA Avelumab (Avel) Folfox, CEA-MUC-TRICOM CV301, or Bacillus Calmette-Guerin (BCG) alone or combined with PANVAC.
  • the additional active agent e.g., chemotherapeutics agent
  • chemotherapeutics agent can be administered before, concurrently with (including simultaneously), alternating with, sequentially, or after administration with the vectors and compositions disclosed herein.
  • one or more (e.g., 2, 3, 4, or 5) chemotherapeutic agents is administered in combination with the vectors and compositions disclosed herein.
  • the additional active agent can be administered alone or in a composition.
  • the additional active agent can be formulated by inclusion in a vector (e.g., plasmid or viral vector), in liposomes (tecemotide, which is also known as STIMUVAXTM, L-BLP25, or BLP25 liposome vaccine), or in nanoparticles (e.g., VERSAMUNETM nanotechnology).
  • a vector e.g., plasmid or viral vector
  • detectemotide which is also known as STIMUVAXTM, L-BLP25, or BLP25 liposome vaccine
  • nanoparticles e.g., VERSAMUNETM nanotechnology.
  • the carrier can be any of those conventionally used and is limited only by physio-chemical considerations, such as solubility and lack of reactivity with the active compound(s), and by the route of administration.
  • pharmaceutically acceptable carriers described herein for example, vehicles, adjuvants, excipients, and diluents, are well-known to those skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active agent(s) and one which has no detrimental side effects or toxicity under the conditions of use.
  • carrier will be determined in part by the particular peptide, polypeptide, nucleic acid, vector, cell, or composition thereof of the invention and other active agents or drugs used, as well as by the particular method used to administer the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof.
  • the composition additionally or alternatively can comprise one or more immunostimulatory/regulatory molecules.
  • immunostimulatory/regulatory molecule can be used, such as interleukin (IL)-2, IL-4, IL-6, IL-12, IL-15, IL-15/IL-15Ra, IL-15/IL-15Ra-Fc, interferon (IFN)-y, tumor necrosis factor (TNF)-a, B7.1, B7.2, ICAM-1, ICAM-2, LFA-1, LFA-2, LFA-3, CD70, CD-72, RANTES, G-CSF, GM-CSF, OX-40L, 41 BBL, anti-CTLA-4, IDO inhibitor, anti-PDLl, anti-PDl, and combinations thereof.
  • IL interleukin
  • IL-4 interleukin
  • IFN interferon
  • TNF tumor necrosis factor
  • B7.1, B7.2 ICAM-1, ICAM-2, LFA-1, LFA-2, LFA-3
  • the IL-12 is NHS-IL12, which is an immunocytokine composed of two IL-12 heterodimers fused to the NHS76 antibody (see Strauss et al., Clinical Cancer Research, 25(1): 99-109 (2019)).
  • the composition comprises a combination of B7.1, ICAM-1, and LFA-3 (also referred to as TRICOM).
  • the one or more immunostimulatory/regulatory molecules can be administered in the form of a vector (e.g., a recombinant viral vector, such as a poxvirus vector) comprising a nucleic acid encoding one or more immunostimulatory/regulatory molecules.
  • the one or more immunostimulatory/regulatory molecules can be administered in the form of a DNA plasmid with or without chitosan.
  • the one or more immunostimulatory/regulatory molecules can be administered as a protein (e.g., recombinant protein), such as a protein (e.g., recombinant IL-12) admixed with chitosan.
  • a protein e.g., recombinant protein
  • a protein e.g., recombinant IL-12
  • One or more immunostimulatory/regulatory molecules also can be administered in combination with, or concurrently with, a yeast-based immunotherapy composition of the invention.
  • the composition comprises a first recombinant vector comprising the nucleic acid encoding the inventive peptide or polypeptide (protein) and second recombinant vector comprising a nucleic acid encoding B7.1, ICAM-1, and LFA-3 (TRICOM).
  • the nucleic acid encoding the inventive peptide or polypeptide (protein) and the nucleic acid encoding B7.1, ICAM-1, and LFA-3 are in the same recombinant vector.
  • the first and/or second vectors additionally can comprise a nucleic acid encoding another tumor associated antigen (e.g., CEA, MUC1, PSA, and/or Brachyury), a modified version thereof (e.g., CEA-6D), or an epitope thereof.
  • the recombinant vector can be an avipox vector (e.g., canarypox virus or a fowlpox virus) comprising the nucleic acid encoding the inventive peptide and nucleic acids encoding a B7-1 polypeptide, an ICAM-1 polypeptide, and an LFA-3 polypeptide.
  • the recombinant vector can be an orthopox virus comprising the nucleic acid encoding the inventive peptide and nucleic acids encoding a B7-1 polypeptide, an ICAM-1 polypeptide, and an LFA-3 polypeptide.
  • the composition comprises a vector comprising the nucleic acid molecule comprising a nucleic acid sequence encoding the peptide or the polypeptide and one or both of anti-PD-Ll and NHS-IL12.
  • the invention provides a method of transducing dendritic cells with the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof, and optionally immunostimulatory/regulatory molecules, such as for example, B7-1, ICAM-1 and LFA-3 (TRICOM).
  • dendritic cells transduced with the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof are administered to the host generate an immune response, such as activation of a cytotoxic T cell response.
  • the invention provides methods of treating a subject suffering from or susceptible to a tumor and/or enhancing an immune response against cancer and/or inhibiting a cancer.
  • the inventive methods comprise administering a therapeutically effective amount of one or more of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to a subject.
  • the inventive peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be used to prevent the development of cancer, particularly in an individual at higher risk to develop such cancer than other individuals, or to treat a patient afflicted with cancer.
  • the inventive peptide, polypeptide, nucleic acid, vector, cell, or composition thereof is useful for preventing emergence of cancer, arresting progression ofcancer or eliminating cancer.
  • inventive peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be used to prevent, inhibit or delay the development of tumors, and/or to prevent, inhibit or delay tumor migration and/or tumor invasion of other tissues (metastases) and/or to generally prevent or inhibit progression of cancer in an individual.
  • inventive peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can also be used to ameliorate at least one symptom of the cancer, such as by reducing tumor burden in the individual; inhibiting tumor growth in the individual; increasing survival of the individual; and/or preventing, inhibiting, reversing or delaying progression of the cancer in the individual.
  • inventive peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be used to treat a subject with any stage of cancer.
  • the inventive methods can comprise obtaining (by isolating) dendritic cells from a subject, treating the dendritic cells with one or more of the therapeutically effective amount of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof, and administering the treated dendritic cells to the subject.
  • the inventive methods can comprise (a) obtaining (isolating) peripheral blood mononuclear cells (PBMCs) from a subject, (b) isolating dendritic cells from the PBMCs, (c) treating the dendritic cells with one or more of the therapeutically effective amount of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof ex vivo, (d) activating the PBMCs with the treated dendritic cells ex vivo, and (e) administering the activated PBMCs to the subject.
  • PBMCs peripheral blood mononuclear cells
  • the inventive methods also can comprise a method for inhibiting cancer in a subject comprising (a) obtaining (isolating) PBMCs from a subject, (b) isolating dendritic cells from the PBMCs, (c) treating the dendritic cells with one or more of the therapeutically effective amount of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof ex vivo, (d) activating the PBMCs with the treated dendritic cells ex vivo, (e) isolating T lymphocytes from the activated PBMCs ex vivo, and (f) administering the isolated T lymphocytes to the subject.
  • the invention also provides the use of adoptively transferred T cells stimulated in vitro with one or more of the therapeutically effective amount of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to inhibit cancer in a subject.
  • the invention also provides T-cell receptor (TCR) engineered T cells and TCR engineered NK cells for treating (e.g., inhibiting) cancer in a subject.
  • TCR engineered T cells and TCR engineered NK cells can be prepared by any suitable methods, such as those described in Ping et al., Protein Cell, 9(3) 254-266 (2016).
  • the TCR engineered T cells and TCR engineered NK cells target cancer cells expressing H, K, and E human endogenous retroviruses (HERVs), such as the epitopes of SEQ ID NOs: 1-41.
  • Treatment comprises, but is not limited to, destroying tumor cells, reducing tumor burden, inhibiting tumor growth, reducing the size of the primary tumor, reducing the number of metastatic legions, increasing survival of the individual, delaying, inhibiting, arresting or preventing the onset or development of metastatic cancer (such as by delaying, inhibiting, arresting or preventing the onset of development of tumor migration and/or tumor invasion of tissues outside of primary cancer and/or other processes associated with metastatic progression of cancer), delaying or arresting primary cancer progression, improving immune responses against the tumor, improving long term memory immune responses against the tumor antigens, and/or improving the general health of the individual.
  • HERVs human endogenous retroviruses
  • tumor cell death can occur without a substantial decrease in tumor size due to, for instance, the presence of supporting cells, vascularization, fibrous matrices, etc. Accordingly, while reduction in tumor size is preferred, it is not required in the treatment of cancer.
  • the cancer can be any cancer, including, but not limited to, cancer of the head and neck, eye, skin, mouth, throat, esophagus, chest, bone, lung, urethra, uterine, bladder, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, fallopian tube, heart or adrenals.
  • cancers include solid tumor, sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelio sarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be administered to the subject by any method.
  • the peptide, polypeptide, or nucleic acid encoding the peptide or polypeptide e.g., as a vector
  • the peptide, polypeptide, or nucleic acid encoding the peptide or polypeptide can be introduced into a cell (e.g., in a host) by any of various techniques, such as by contacting the cell with the peptide, polypeptide, the nucleic acid, or a composition comprising the nucleic acid as part of a construct, as described herein, that enables the delivery and expression of the nucleic acid.
  • Specific protocols for introducing and expressing nucleic acids in cells are known in the art.
  • Suitable methods of administering peptides, polypeptides (proteins), nucleic acids, vectors, cells, and compositions to hosts (subjects) are known in the art.
  • the host can be any suitable host, such as a mammal (e.g., a rodent, such as a mouse, rat, hamster, or guinea pig, rabbit, cat, dog, pig, goat, cow, horse, primate, or human).
  • the peptide, polypeptide, nucleic acid, or vector can be administered to a host by exposure of tumor cells to the peptide, polypeptide, nucleic acid, or vector ex vivo or by injection of the peptide, polypeptide, nucleic acid, or vector into the host.
  • the peptide, polypeptide, nucleic acid, vector (e.g., recombinant poxvirus) or combination of vectors, cell, and composition can be directly administered (e.g., locally administered) by direct injection into the cancerous lesion or tumor or by topical application (e.g., with a pharmaceutically acceptable carrier).
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be administered alone or in combination with adjuvants, incorporated into liposomes (as described in, e.g., U.S. Patent Nos. 5,643,599, 5,464,630, 5,059,421, and 4,885,172), incorporated into nanoparticles (e.g., VERSAMUNETM nanotechnology), administered with cytokines, administered with biological response modifiers (e.g., interferon, interleukin-2 (IL-2), administered colony-stimulating factors (CSF, GM-CSF, and G-CSF), and/or administered other reagents in the art that are known to enhance immune response.
  • adjuvants e.g., incorporated into liposomes (as described in, e.g., U.S. Patent Nos. 5,643,599, 5,464,630, 5,059,421, and 4,885,172), incorporated into nanoparticles (e.g
  • Suitable adjuvants include alum, aluminum salts, aluminum phosphate, aluminum hydroxide, aluminum silica, calcium phosphate, incomplete Freund’s adjuvant, saponins, such as QS21 (an immunological adjuvant derived from the bark of the South American tree Quillaja saponaria Molina), monophosphoryl lipid A (MLP-A), and RIBI DETOXTM adjuvant.
  • QS21 an immunological adjuvant derived from the bark of the South American tree Quillaja saponaria Molina
  • MLP-A monophosphoryl lipid A
  • RIBI DETOXTM adjuvant examples include RIBI DETOXTM adjuvant.
  • the adjuvant for use in the invention is the cytokine GM-CSF.
  • GM-CSF has been shown to be an effective vaccine adjuvant because it enhances antigen processing and presentation by dendritic cells. Experimental and clinical studies suggest that recombinant GM-CSF can boost host immunity directed at a variety of immunogens.
  • GM-CSF can be administered using a viral vector (e.g., poxvirus vector) or as an isolated protein in a pharmaceutical formulation.
  • GM-CSF can be administered to the host before, during, or after the initial administration of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to enhance the antigen-specific immune response in the host.
  • recombinant GM-CSF protein can be administered to the host on each day of vaccination with the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof and for each of the following 3 days (i.e. a total of 4 days).
  • Any suitable dose of GM-CSF can be used.
  • 50-500 pg e.g., 100 pg, 200 pg, 300 pg, 400 pg, and ranges therebetween
  • recombinant GM-CSF can be administered per day.
  • the GM-CSF can be administered by any suitable method (e.g., subcutaneously) and, preferably, is administered at or near the site of the vaccination of a host with the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof.
  • the inventive peptide or polypeptide (protein) can be conjugated to helper peptides or to large carrier molecules to enhance the immunogenicity of the peptide or polypeptide.
  • helper peptides or to large carrier molecules include, but are not limited to, influenza peptide, tetanus toxoid, tetanus toxoid CD4 epitope, Pseudomonas exotoxin A, poly-L-lysine, a lipid tail, endoplasmic reticulum (ER) signal sequence, and the like.
  • the inventive peptide or polypeptide (protein) also can be conjugated to an immunoglobulin molecule using art-accepted methods.
  • the immunoglobulin molecule can be specific for a surface receptor present on tumor cells, but absent or in very low amounts on normal cells.
  • the immunoglobulin also can be specific for a specific tissue (e.g., breast, ovarian, colon, or prostate tissue).
  • tissue e.g., breast, ovarian, colon, or prostate tissue.
  • Such a peptide-immunoglobulin conjugate or polypeptide-immunoglobulin conjugate allows for targeting of the peptide to a specific tissue and/or cell.
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof is administered to a host (e.g., mammal, such as a human) in an amount effective to generate an immune response, preferably a cellular immune response.
  • a host e.g., mammal, such as a human
  • the efficacy of the peptide, polypeptide, nucleic acid, vector, or cell as an immunogen may be determined by in vivo or in vitro parameters as are known in the art. These parameters include but are not limited to antigen-specific cytotoxicity assays, regression of tumors, inhibition of cancer cells, production of cytokines, and the like.
  • any suitable dose of the peptide, polypeptide, nucleic acid, vector, or cell or composition thereof can be administered to a host.
  • the appropriate dose will vary depending upon such factors as the host’s age, weight, height, sex, general medical condition, previous medical history, disease progression, and tumor burden and can be determined by a clinician.
  • the peptide can be administered in a dose of about 0.05 mg to about 10 mg (e.g., 0.1 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, and ranges therebetween) per vaccination of the host (e.g., mammal, such as a human), and preferably about 0.1 mg to about 5 mg per vaccination.
  • Several doses e.g., 1, 2, 3, 4, 5, 6, or more
  • a dose is provided every month for 3 months.
  • a suitable dose can include about 1 x 10 5 to about 1 x 10 12 (e.g., 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x 10 10 , 1 x 10 11 , and ranges therebetween) plaque forming units (pfus), although a lower or higher dose can be administered to a host.
  • pfus plaque forming units
  • about 2 x 10 8 pfus can be administered (e.g., in a volume of about 0.5 mL).
  • the inventive cells can be administered to a host in a dose of between about 1 x 10 5 and 2 x 10 11 (e.g., 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x 10 10 , and ranges therebetween) cells per infusion.
  • the cells can be administered in, for example, one to three (e.g., one, two, or three) infusions.
  • the host can be administered a biological response modifier, such as interleukin 2 (IL- 2).
  • IL-2 interleukin 2
  • the administration of the cytotoxic T cells can be followed by the administration of the peptide, polypeptide, nucleic acid, vector, or composition thereof in order to prime the cytotoxic T cells to further expand the T cell number in vivo.
  • the amount of dendritic cells administered to the subject will vary depending on the condition of the subject and should be determined via consideration of all appropriate factors by the practitioner.
  • about lxlO 6 to about lxlO 12 e.g., about lxlO 7 , about lxlO 8 , about lxlO 9 , about lxlO 10 , or about lxlO 11 including ranges between of any of the cell numbers described herein
  • dendritic cells are utilized for adult humans.
  • the invention provides a method of generating peptide-specific cytotoxic T lymphocytes in vivo, ex vivo, or in vitro by stimulation of lymphocytes with an effective amount of the inventive peptide, polypeptide, nucleic acid, vector, or cell, alone or in a composition with one or more immunostimulatory/regulatory molecules and/or adjuvants or in a liposome formulation.
  • the lymphocytes can be lymphocytes from any suitable source, e.g., peripheral blood, tumor tissues, lymph nodes, and effusions, such as pleural fluid or ascites fluid.
  • the HERVs peptide specific cytotoxic T lymphocytes are immunoreactive.
  • the cytotoxic T lymphocytes inhibit the occurrence of tumor cells and cancer and inhibit the growth of, or kill, tumor cells.
  • the cytotoxic T lymphocytes in addition to being antigen specific, can be MHC class (e.g., MHC class I) restricted.
  • the cytotoxic T lymphocytes preferably have a CD8 + phenotype.
  • lymphocytes are removed from the host and stimulated ex vivo with the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to generate cytotoxic T lymphocytes.
  • the cytotoxic T lymphocytes can be administered to the host in order to enhance an immune response to cancer, thereby inhibiting the cancer.
  • the invention provides a method of inhibiting cancer in a host comprising (a) obtaining lymphocytes (e.g., from the host), (b) stimulating the lymphocytes with the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to generate cytotoxic T lymphocytes, and (c) administering the cytotoxic T lymphocytes to the host, wherein the cancer is inhibited.
  • lymphocytes within the host are stimulated by administration to the host of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to generate cytotoxic T lymphocytes, which cytotoxic T lymphocytes enhance an immune response to cancer, thereby inhibiting the cancer.
  • the invention includes a prime and boost protocol.
  • the protocol includes an initial “prime” with a composition comprising one or more recombinant vectors encoding the inventive peptide or polypeptide and optionally one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens (e.g., CEA, MUC1, PSA, and/or Brachyury), modified versions thereof, and immunogenic epitopes thereof, followed by one or preferably multiple “boosts” with a composition containing the inventive peptide or polypeptide or one or more poxvirus vectors encoding the inventive peptide or polypeptide and optionally one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens (e.g., CEA, MUC1, PSA, and/or Brachyury), modified versions thereof, and immunogenic epitopes thereof.
  • a composition comprising one or more recombinant vectors encoding the inventive peptide or polypeptide and optionally one or
  • the initial priming vaccination can comprise one or more vectors.
  • a single vector e.g., poxvirus vector
  • one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens e.g., CEA, MUC1, PSA, and/or Brachyury
  • two or more vectors e.g., poxvirus vectors
  • the boosting vaccinations also can comprise one or more vectors (e.g., poxvirus vectors).
  • a single vector is used for delivery of the inventive peptide and the one or more immunostimulatory/regulatory molecules and/or other tumor- associated antigens (e.g., CEA, MUC1, PSA, and/or Brachyury), modified versions thereof, and immunogenic epitopes thereof of the boosting vaccination.
  • two or more vectors comprise the boosting vaccination, which are administered simultaneously in a single injection.
  • Different vectors e.g., poxvirus vectors
  • Different vectors can be used to provide a heterologous prime/boost protocol using vectors carrying different sets of therapeutic molecules for inoculations at different time intervals. For example, in one heterologous prime/boost combination, a first orthopox vector composition is used to prime, and a second avipox vector composition is used to boost.
  • the schedule for administration of the vectors typically involves repeated administration of the boosting vector.
  • the boosting vector can be administered 1-3 times (e.g., 1, 2, or 3 times) at any suitable time period (e.g., every 2-4 weeks) for any suitable length of time (e.g., 6-12 weeks for a total of at least 5 to 15 boosting vaccinations).
  • the primary vaccination can comprise a recombinant vaccinia or MV A vector followed by multiple booster vaccinations with an avipox vector.
  • the host receives one vaccination with the priming vector, followed every 2 weeks thereafter with the boosting vector for 6 boosts, followed by every 4 weeks thereafter with the boosting vector, and continuing with the boosting vector for a period of time dependent on disease progression.
  • the invention further provides a kit that, in one embodiment, has at least a first recombinant vector (e.g., poxvirus vector) that has incorporated into its genome or portion thereof a nucleic acid encoding the inventive peptide or polypeptide in a pharmaceutically acceptable carrier.
  • the first recombinant vector e.g., poxvirus vectors
  • the first recombinant vector also can comprise one or more nucleic acids encoding one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens (e.g., CEA, MUC1, PSA, and/or Brachyury), modified versions thereof, and immunogenic epitopes thereof.
  • the kit can have a second recombinant vector that comprises one or more nucleic acids encoding one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens (e.g., CEA, MUC1, PSA, and/or Brachyury), modified versions thereof, and immunogenic epitopes thereof in a pharmaceutically acceptable carrier.
  • the kit further provides containers, injection needles, and instructions on how to use the kit.
  • the kit further provides an adjuvant such as GM-CSF and/or instructions for use of a commercially available adjuvant with the kit components.
  • the invention provides a method of inducing an immune response against cancer in a subject comprising (a) administering to the subject a first vector (e.g., viral vector, such as a poxviral vector) comprising a nucleic acid encoding the amino acid sequence of any one of SEQ ID NOs: 1-41 and (b) administering to the subject a second vector (e.g., viral vector, such as a poxviral vector) comprising a nucleic acid encoding the amino acid sequence of any one of claims 1-41.
  • a first vector e.g., viral vector, such as a poxviral vector
  • a second vector e.g., viral vector, such as a poxviral vector
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be administered to a host by various routes including, but not limited to, subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, and intratumoral.
  • the administrations can be at one or more sites in a host and a single dose can be administered by dividing the single dose into equal portions for administration at one, two, three, four or more sites on the individual.
  • Administration of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be “prophylactic” or “therapeutic.”
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof is provided in advance of tumor formation, or the detection of the development of tumors, with the goal of preventing, inhibiting or delaying the development of tumors; and/or preventing, inhibiting or delaying metastases of tumors and/or generally preventing or inhibiting progression of cancer in an individual, and generally to allow or improve the ability of the host’s immune system to fight against a tumor that the host is susceptible of developing.
  • the prophylactic administration of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof prevents, ameliorates, or delays the cancer.
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof is provided at or after the diagnosis of the cancer, with the goal of ameliorating the cancer, such as by reducing tumor burden in the individual; inhibiting tumor growth in the individual; increasing survival of the individual; and/or preventing, inhibiting, reversing or delaying progression of the cancer in the individual.
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be administered in conjunction with other therapeutic treatments such as chemotherapy, surgical resection of a tumor, treatment with targeted cancer therapy, allogeneic or autologous stem cell transplantation, T cell adoptive transfer, other immunotherapies, and/or radiation.
  • cancer e.g., metastatic cancer
  • other therapeutic treatments such as chemotherapy, surgical resection of a tumor, treatment with targeted cancer therapy, allogeneic or autologous stem cell transplantation, T cell adoptive transfer, other immunotherapies, and/or radiation.
  • the administration of the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof to a host results in a host cell expressing the inventive peptide and optionally one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens (e.g., CEA, MUC1, PSA, and/or Brachyury), modified versions thereof, and immunogenic epitopes thereof that were co-administered.
  • the inventive peptide can be expressed at the cell surface of the infected host cell.
  • the one or more immunostimulatory/regulatory molecules and/or other tumor-associated antigens can be expressed at the cell surface or may be actively secreted by the host cell.
  • the expression of both the peptide and the immunostimulatory/regulatory molecule provides the necessary MHC restricted peptide to specific T cells and the appropriate signal to the T cells to aid in antigen recognition and proliferation or clonal expansion of antigen specific T cells.
  • the overall result is an upregulation of the immune system.
  • the upregulation of the immune response is an increase in antigen specific T-helper lymphocytes and/or cytotoxic lymphocytes, which are able to kill or inhibit the growth of a cancer cell.
  • compositions for the inventive methods there are a variety of suitable formulations of the pharmaceutical composition for the inventive methods.
  • parenteral, subcutaneous, intravenous, intramuscular, and intraperitoneal administration are exemplary and are in no way limiting.
  • routes of administering the peptide, polypeptide, nucleic acid, vector, cell, or composition of the invention are known, and, although more than one route can be used to administer a particular compound, a particular route can provide a more immediate and more effective response than another route.
  • injectable formulations are among those formulations that are preferred in accordance with the present invention.
  • the requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986)).
  • Formulations suitable for parenteral administration include aqueous and non- aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the peptide, polypeptide, nucleic acid, vector, cell, or composition thereof can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol ketals, such as 2,2-dimethyl-l,3- dioxolane-4-methanol, ethers, such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose,
  • Oils which can be used in parenteral formulations, include petroleum, animal, vegetable, and synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, com, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
  • Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
  • suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-b-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.
  • Preservatives and buffers may be used.
  • such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17.
  • HLB hydrophile-lipophile balance
  • Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
  • sterile liquid excipient for example, water
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
  • This example demonstrates the identification of human immunogenic epitopes of H, K, and E HERVs.
  • HERV-H1 env, HERV-H3 env and HERV-K env transcripts were evaluated by by RT-PCR in a range of human normal tissues (Figure 1) and human tumor tissues ( Figure 2). Overexpression of these transcripts was observed in tumors vs. normal tissues ( Figure 3).
  • Agonist epitopes were also evaluated and in one case (an HERV-H peptide), the agonist showed greater binding to HLA-A2 than its native counterpart ( Figure 4).
  • This example further characterizes the human immunogenic epitopes of H, K, and E HERVs.
  • Table 7 T-cell responses to HERV H env 15-mer pool after immunotherapy in advanced cancer patients.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV H env 15-mer Peptides (Table 1) and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Tables 6 and 7 indicate the absolute number of CD4 + or CD8 + T cells producing cytokine or positive for CD107a per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with the HERV H env 339 Agonist or HERV H env 339 Native 9-mer peptide (Table 1) and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Table 8 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD107a per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV K env 15-mer peptides (Table 2) and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Table 9 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD 107a per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV K gag 15-mer peptides (Table 2), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a.
  • Values in Table 10 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD107a per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV E env 15-mer peptides (Table 3), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a.
  • Values in Tables 11 and 12 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD107a per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • T cells were shown to be multifunctional, expressing more than 1 Type I cytokine and/or CD107a, indicative of a more lytic function (Tables 13- 19).
  • Table 13 Multifunctional T-cell responses to HERV H env 15-mer pool after immunotherapy.
  • Table 14 Multifunctional T cell responses to a pool of 15-mer HERV H env peptides following immunotherapy in advanced cancer patients.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV H env 15-mer Peptides (Table 1), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a.
  • Values in Tables 13 and 14 indicate the absolute number of T cells positive for 2 or more markers (IFNg, IL-2, TNF, CD107a) per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide. er
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with the HERV H env 339 Agonist or HERV H env 339 Native 9-mer peptide (Table 1), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a. Values in Table 15 indicate the absolute number of T cells positive for 2 or more markers (IFNg, IL-2, TNF, CD107a) per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide. [00155] Table 16. Multifunctional T-cell responses to HERV K env 15-mer pool after immunotherapy.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV H env 15-mer Peptides (Table 2), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a.
  • Values in Table 16 indicate the absolute number of T cells positive for 2 or more markers (IFNg, IL-2, TNF, CD107a) per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • Table 17 Multifunctional T-cell responses to HERV K gag 15-mers after immunotherapy.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV K gag 15-mer Peptides (Table 2) and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Table 17 indicate the absolute number of T cells positive for 2 or more markers (IFNg, IL-2, TNF, CD107a) per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • Table 18 Multifunctional T-cell Responses to HERV E env 15-mer pool after immunotherapy.
  • Table 19 Multifunctional T-cell responses to a pool of 15-mer HERV E env peptides following immunotherapy in advanced cancer patients.
  • PBMCs obtained from cancer patients following immunotherapy were stimulated with a pool of HERV E env 15-mer Peptides (Table 3) and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Tables 18 and 19 indicate the absolute number of T cells positive for 2 or more markers (IFNg, IL-2, TNF, CD107a) per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • PBMCs obtained from cancer patients before and after immunotherapy were stimulated with a pool of HERV H env 15-mer Peptides (Table 1), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a.
  • Values in Tables 20 and 21 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD107a per lxlO 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • Table 22 T-cell Responses to HERV H env 9-mers before and after immunotherapy.
  • PBMCs obtained from cancer patients before and after immunotherapy were stimulated with the HERV H env 339 Agonist or HERV H env 339 Native 9-mer peptide (Table 1), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Table 22 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD107a per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • Table 23 T-cell Responses to HERV E env 15-mer pool before and after immunotherapy.
  • Table 24 T-cell responses to a pool of 15-mer HERV E env peptides before and after immunotherapy in advanced cancer patients.
  • PBMCs obtained from cancer patients before and after immunotherapy were stimulated with a pool of HERV E env 15-mer Peptides (Table 3), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD107a.
  • Values in Tables 23 and 24 indicate the absolute number of CD4+ or CD8+ T cells producing cytokine or positive for CD107a per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control peptide.
  • Table 25 Multifunctional T-cell responses to HERV H env 15-mer pool and 9- mers and Herv E env 15-mer pool before and after immunotherapy.
  • Table 26 Multifunctional T cell responses to a pool of 15-mer HERV H env peptides before and after immunotherapy in advanced cancer.
  • PBMCs obtained from cancer patients before and after immunotherapy were stimulated with either a pool of HERV H env 15-mers, the HERV H env 339 Agonist 9-mer peptide, the HERV H env 339 Native 9-mer peptide (Table 1), or a pool of HERV E env 15-mers (Table 3), and T cells were assessed for the production of cytokine or positivity for the degranulation marker CD 107a.
  • Values in Tables 25-27 indicate the absolute number of T cells positive for 2 or more markers (IFNg, IL-2, TNF, CD107a) per 1x10 6 PBMCs. Background was subtracted. Values were considered a response (in bold) if >250 and >2 fold-change vs the negative control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un épitope agoniste des lymphocytes T cytotoxiques humains de rétrovirus endogènes humains H, K et E, qui peut être utilisé en tant que peptide, polypeptide (protéine) et/ou dans des vaccins ou une autre composition utilisable en vue de la prévention ou du traitement du cancer. L'invention concerne en outre un acide nucléique codant pour le peptide ou le polypeptide (protéine), un vecteur comprenant l'acide nucléique, une cellule comprenant le peptide, le polypeptide (protéine), l'acide nucléique ou le vecteur et des compositions de ceux-ci.
PCT/US2021/014360 2020-01-21 2021-01-21 Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e WO2021150713A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062963856P 2020-01-21 2020-01-21
US62/963,856 2020-01-21

Publications (2)

Publication Number Publication Date
WO2021150713A2 true WO2021150713A2 (fr) 2021-07-29
WO2021150713A3 WO2021150713A3 (fr) 2021-10-07

Family

ID=74626199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/014360 WO2021150713A2 (fr) 2020-01-21 2021-01-21 Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e

Country Status (1)

Country Link
WO (1) WO2021150713A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144231A1 (fr) * 2022-01-25 2023-08-03 Ervaccine Technologies Nouvelle méthode d'identification d'épitopes dérivés d'herv
CN117591812A (zh) * 2024-01-18 2024-02-23 山东黄海智能装备有限公司 一种智能电子听诊器电信号降噪处理优化方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5464630A (en) 1990-07-27 1995-11-07 Research Development Foundation Liposomes that provide thymic dependent help to weak vaccine antigens
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6193752B1 (en) 1997-07-09 2001-02-27 Peter Hildebrandt Urological implant, in particular vascular wall support for the urinary tract
WO2002042480A2 (fr) 2000-11-23 2002-05-30 Bavarian Nordic A/S Variant du virus de la vaccine modified vaccinia ankara
WO2005048957A2 (fr) 2003-02-20 2005-06-02 Therion Biologics Corporation Nouveaux sites d'insertion dans des vecteurs de variole
US7211432B2 (en) 1998-12-09 2007-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vector expressing multiple costimulatory molecules and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236534A1 (en) * 2000-11-20 2002-05-27 Diadexus, Inc. Compositions and methods relating to ovary specific genes and proteins
EP2340851A4 (fr) * 2008-09-18 2012-09-26 Univ Keio Procédé de diagnostic et procédé thérapeutique pour le cancer
WO2014004385A2 (fr) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Vaccins anticancéreux

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5464630A (en) 1990-07-27 1995-11-07 Research Development Foundation Liposomes that provide thymic dependent help to weak vaccine antigens
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6193752B1 (en) 1997-07-09 2001-02-27 Peter Hildebrandt Urological implant, in particular vascular wall support for the urinary tract
US7211432B2 (en) 1998-12-09 2007-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vector expressing multiple costimulatory molecules and uses thereof
WO2002042480A2 (fr) 2000-11-23 2002-05-30 Bavarian Nordic A/S Variant du virus de la vaccine modified vaccinia ankara
US6761893B2 (en) 2000-11-23 2004-07-13 Bavarian Nordic A/S Modified vaccinia ankara virus variant
WO2005048957A2 (fr) 2003-02-20 2005-06-02 Therion Biologics Corporation Nouveaux sites d'insertion dans des vecteurs de variole

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"ASHP Handbook on Injectable Drugs", 1986, TOISSEL, pages: 622 - 630
"Pharmaceutics and Pharmacy Practice", 1982, J.B. LIPPINCOTT COMPANY, pages: 238 - 250
ANTOINE ET AL., VIROL., vol. 244, 1998, pages 365 - 396
BOUKAMP ET AL., J. CELL BIOL., vol. 106, no. 3, 1988, pages 761 - 71
COSMA ET AL., VACCINE, vol. 22, no. 1, 2003, pages 21 - 29
DI NICOLA ET AL., CLIN. CANCER RES., vol. 10, no. 16, 2004, pages 5381 - 5390
DI NICOLA ET AL., HUM. GENE THER., vol. 14, no. 14, 2003, pages 1347 - 1360
HARRER ET AL., ANTIVIR. THER., vol. 10, no. 2, 2005, pages 285 - 300
MARY ET AL., ZBL. BAKT. HYG. I, ABT. ORG. B, vol. 167, 1987, pages 375 - 390
MAYR ET AL., DEV. BIOL. STAND., vol. 41, 1978, pages 225 - 34
MAYR ET AL., INFECTION, vol. 3, 1975, pages 6 - 14
MEYER ET AL., GEN. VIROL., vol. 72, 1991, pages 1031 - 1038
MEYER ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038
PING ET AL., PROTEIN CELL, vol. 9, no. 3, 2018, pages 254 - 266
RAMIREZ ET AL., J. VIROL., vol. 74, 2000, pages 7651 - 7655
STICKL ET AL., DTSCH. MED. WSCHR., vol. 99, 1974, pages 2386 - 2392
STRAUSS ET AL., CLINICAL CANCER RESEARCH, vol. 25, no. 1, 2019, pages 99 - 109
SUTTER ET AL., PROC. NAT 'I ACAD. SCI. USA, vol. 89, 1992, pages 10847 - 10851

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144231A1 (fr) * 2022-01-25 2023-08-03 Ervaccine Technologies Nouvelle méthode d'identification d'épitopes dérivés d'herv
CN117591812A (zh) * 2024-01-18 2024-02-23 山东黄海智能装备有限公司 一种智能电子听诊器电信号降噪处理优化方法
CN117591812B (zh) * 2024-01-18 2024-04-26 中国人民解放军总医院第二医学中心 一种智能电子听诊器电信号降噪处理优化方法

Also Published As

Publication number Publication date
WO2021150713A3 (fr) 2021-10-07

Similar Documents

Publication Publication Date Title
US11732017B2 (en) HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
US20210299236A1 (en) Methods and Compositions for Enhancing Vaccine Immune Responses
WO2014043535A9 (fr) Compositions destinées à traiter le cancer
WO2021150713A2 (fr) Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e
AU2017355564B2 (en) Development of agonist epitopes of the human papillomavirus
US20230287067A1 (en) Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)
US8367069B2 (en) Cytotoxic T cell defined EGFR peptide and an optimized derivative peptide
US20220009980A1 (en) Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21705774

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21705774

Country of ref document: EP

Kind code of ref document: A2